All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TG Therapeutics: Entering 2025 With Increased Investor Expectations
TG Therapeutics presented at the JP Morgan Healthcare conference this month and CEO Weiss provided commercial and pipeline updates. Briumvi's strong Q4 2024 performance, with $103.6 million in net sales, and 2025 outlook highlight its growth potential despite recent new competition from Roche's Ocrevus Zunovo. Pipeline updates include subcutaneous Briumvi entering phase 3 trials in mid-2025 and new trials to improve IV Briumvi's convenience, alongside expansion into myasthenia gravis.
TG Therapeutics: 2025 Revenues Will Smash Expectations
TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth and market share capture with its Multiple Sclerosis treatment, Briumvi. 2025 revenue guidance of $540 million implies slower growth, but management and data suggest potential for significantly higher revenue, possibly reaching $605 million. CEO comments and Q4 performance indicate sustained 15-20% new patient growth, bolstered by upcoming advertisements and increased visibility among key opinion leaders.
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
TG Therapeutics reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides revenue guidance for 2025 and other pipeline goals.
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst
TG Therapeutics is already marketing an IV infusion of Briumvi, but is also developing a subcutaneous form, which could help it compete with other multiple sclerosis drugs. The company expects to report initial data on the subcutaneous form of Briumvi in early 2025, which could be positive given the company's upbeat statements on its prospects. While the company has approved a $100M share buyback, it only bought back $2.1M in Q3'24. Further buybacks could limit downside in the stock.
TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but generally in line with management expectations of a softer Q3. Now we wait for the important updates in early 2025 — preliminary Q4 net sales of Briumvi, the guidance for 2025, and the preliminary results from subcutaneous Briumvi's trial.
TG Therapeutics Posts Strong Q3 Briumvi Revenue, Here's Why Shares Fell
TG Therapeutics' Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and increased R&D investments, despite Briumvi's revenue growth. Briumvi, a CD20-directed monoclonal antibody for multiple sclerosis, generated $83.3 million in Q3, showing a 15% QoQ growth but a deceleration in revenue growth. The Company raised its full-year revenue guidance to $300-305 million, indicating confidence in Briumvi's market performance despite competitive pressures from Ocrevus and Kesimpta.
TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Ed White - H.C. Wainwright Michael DiFiore - Evercore ISI Eric Joseph - JP Morgan Tara Bancroft - TD Cowen Matt Kaplan - Ladenburg Thalmann Mayank Mamtani - B.
TG Therapeutics (TGTX) Lags Q3 Earnings Estimates
TG Therapeutics (TGTX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.73 per share a year ago.
TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
TG Therapeutics exceeded Q2 Street consensus estimates, with Briumvi net sales of $72.6 million and total revenues of $73.5 million. Positive cash flow achieved one quarter ahead of my expectations, and full-year guidance range raised by $15 million at the mid-point of the range. TG secured a new $250 million credit facility to retire the old one, and it will use $100 million to buy back shares.
TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates
TG Therapeutics (TGTX) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.34 per share a year ago.
